Bio-pharma major Biocon is on an expansion mode. The biotech major plans to invest close to Rs 100 crore on its new research and development center located in Bangalore, with a window for future investments going up to Rs 200 crore in next few years.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.